Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine

Transfusion and Apheresis Science

Volumn 54, Issue 2, 2016, Pages 309-318

  Wu, Yu Wen ^a   Goubran, Hadi ^b   Seghatchian, Jerard ^c   Burnouf, Thierry ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

Author keywords

Drug carriers; Drug delivery; Microvescicles; Platelets; Red blood cells

Indexed keywords

CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEM; ERYTHROCYTE MEMBRANE; HUMAN; INFLAMMATION; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROCEDURES;

CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; ERYTHROCYTE MEMBRANE; HUMANS; INFLAMMATION; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84969961766     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2016.04.013     Document Type: Review

References (86)

1. Morales JO, Sepulveda-Rivas S, Oyarzun-Ampuero F, Lavandero S, Kogan MJ Novel nanostructured polymeric carriers to enable drug delivery for cardiovascular diseases. Curr Pharm Des 2015, 21:4276-4284.
2. Pehlivan SB Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res 2013, 30:2499-2511.
3. Liu D, Auguste DT Cancer targeted therapeutics: from molecules to drug delivery vehicles. J Control Release 2015, 219:632-643.
4. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 2015, 21:223-232.
5. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2015, 200:138-157.
6. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets 2011, 12:1151-1165.
7. Muthu MS, Feng SS Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success. Expert Opin Drug Deliv 2013, 10:151-155.
8. Hyodo K, Yamamoto E, Suzuki T, Kikuchi H, Asano M, Ishihara H Development of liposomal anticancer drugs. Biol Pharm Bull 2013, 36:703-707.
9. Tan S, Wu T, Zhang D, Zhang Z Cell or cell membrane-based drug delivery systems. Theranostics 2015, 5:863-881.
10. Song G, Wu H, Yoshino K, Zamboni WC Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 2012, 22:177-192.
11. Knop K, Hoogenboom R, Fischer D, Schubert US Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010, 49:6288-6308.
12. Gabizon AA, Shmeeda H, Zalipsky S Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006, 16:175-183.
13. Batrakova EV, Kim MS Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 2015, 219:396-405.
14. Torchilin VP Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
15. Yoo JW, Irvine DJ, Discher DE, Mitragotri S Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011, 10:521-535.
16. Demirer GS, Okur AC, Kizilel S Synthesis and design of biologically inspired biocompatible iron oxide nanoparticles for biomedical applications. J Mater Chem B Mater Biol Med 2015, 3:7831-7849.
17. Muzykantov VR Drug delivery carriers on the fringes: natural red blood cells versus synthetic multilayered capsules. Expert Opin Drug Deliv 2013, 10:1-4.
18. Hu CM, Fang RH, Zhang L Erythrocyte-inspired delivery systems. Adv Healthc Mater 2012, 1:537-547.
19. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011, 108:10980-10985.
20. Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA 2009, 106:21495-21499.
21. Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015, 526:118-121.
22. Pan V, Siva PN, Modery-Pawlowski CL, Sekhon UDS, Sen Gupta A Targeted killing of metastatic cells using a platelet-inspired drug delivery system. RSC Adv 2015, 5:46218-46228.
23. Li J, Ai Y, Wang L, Bu P, Sharkey CC, Wu Q, et al. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials 2016, 76:52-65.
24. Yousefpour P, Chilkoti A Co-opting biology to deliver drugs. Biotechnol Bioeng 2014, 111:1699-1716.
25. Snyder EL, Stramer SL, Benjamin RJ The safety of the blood supply - time to raise the bar. N Engl J Med 2015, 372:1882-1885.
26. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015, 52:19-34.
27. Godfrin Y, Horand F, Franco R, Dufour E, Kosenko E, Bax BE, et al. International seminar on the red blood cells as vehicles for drugs. Expert Opin Biol Ther 2012, 12:127-133.
28. Muzykantov VR Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010, 7:403-427.
29. Gupta A, Mishra A, Bansal P, Kumar S, Gupta V, Singh R, et al. Cell based drug delivery system through resealed erythrocyte - a review. Int J Pharm Sci Drug Res 2010, 1:23-30.
30. Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 2007, 118:145-160.
31. Wang C, Sun X, Cheng L, Yin S, Yang G, Li Y, et al. Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer. Adv Mater 2014, 26:4794-4802.
32. Magnani M, Pierigè F, Rossi L Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. Ther Deliv 2012, 3:405-414.
33. Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 2013, 20:392-402.
34. Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011, 153:58-65.
35. Hunault-Berger M, Leguay T, Huguet F, Lepretre S, Deconinck E, Ojeda-Uribe M, et al. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL/GRAALL-SA2-2008 study. Am J Hematol 2015, 90:811-818.
36. Bachet JB, Gay F, Marechal R, Galais MP, Adenis A, Ms CD, et al. Asparagine synthetase expression and phase I study with L-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas 2015, 44:1141-1147.
37. Chessa L, Leuzzi V, Plebani A, Soresina A, Micheli R, D'Agnano D, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis 2014, 9:5.
38. Cremel M, Guerin N, Campello G, Barthe Q, Berlier W, Horand F, et al. Innovative approach in Pompe disease therapy: induction of immune tolerance by antigen-encapsulated red blood cells. Int J Pharm 2015, 491:69-77.
39. Banz A, Cremel M, Mouvant A, Guerin N, Horand F, Godfrin Y Tumor growth control using red blood cells as the antigen delivery system and poly (I: C). J Immunother 2012, 35:409-417.
40. Gresele PPC, Fuster V, Vermylen J Platelets in thrombotic and non-thrombotic disorders 2002, 25. Cambridge University Press.
41. Burnouf T, Strunk D, Koh MB, Schallmoser K Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials 2016, 76:371-387.
42. Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray PF MicroRNAs in platelet production and activation. J Thromb Haemost 2013, 11(Suppl. 1):340-350.
43. Rowley JW, Schwertz H, Weyrich AS Platelet mRNA: the meaning behind the message. Curr Opin Hematol 2012, 19:385-391.
44. Gnatenko DV, Perrotta PL, Bahou WF Proteomic approaches to dissect platelet function: half the story. Blood 2006, 108:3983-3991.
45. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009, 7:241-246.
46. Nachman RL, Rafii S Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008, 359:1261-1270.
47. Adelson E, Rheingold JJ, Crosby WH The platelet as a sponge: a review. Blood 1961, 17:767-774.
48. King GL, Buchwald S Characterization and partial purification of an endothelial cell growth factor from human platelets. J Clin Invest 1984, 73:392-396.
49. Burnouf T, Goubran HA, Chen TM, Ou KL, El-Ekiaby M, Radosevic M Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev 2013, 27:77-89.
50. Semple JW, Italiano JE, Freedman J Platelets and the immune continuum. Nat Rev Immunol 2011, 11:264-274.
51. Fuentes QE, Fuentes QF, Andres V, Pello OM, Font de Mora J, Palomo GI Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2013, 24:255-262.
52. Nurden AT Platelets, inflammation and tissue regeneration. Thromb Haemost 2011, 105(Suppl. 1):S13-33.
53. Goubran HA, Stakiw J, Radosevic M, Burnouf T Platelet-cancer interactions. Semin Thromb Hemost 2014, 40:296-305.
54. Goubran HA, Stakiw J, Radosevic M, Burnouf T Platelets effects on tumor growth. Semin Oncol 2014, 41:359-369.
55. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
56. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16:585-601.
57. Schallmoser K, Rohde E, Bartmann C, Obenauf AC, Reinisch A, Strunk D Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. Biomed Mater Eng 2009, 19:271-276.
58. Golebiewska EM, Poole AW Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev 2015, 29:153-162.
59. Broos K, De Meyer SF, Feys HB, Vanhoorelbeke K, Deckmyn H Blood platelet biochemistry. Thromb Res 2012, 129:245-249.
60. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 2014, 33:231-269.
61. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis 2014, 7:9-18.
62. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M The platelet-cancer loop. Eur J Intern Med 2013, 24:393-400.
63. Lowe KL, Navarro-Nunez L, Watson SP Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012, 129(Suppl. 1):S30-7.
64. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Du LM, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007, 5:352-361.
65. Sarkar S, Alam MA, Shaw J, Dasgupta AK Drug delivery using platelet cancer cell interaction. Pharm Res 2013, 30:2785-2794.
66. Mooberry MJ, Key NS Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A 2016, 89:111-122.
67. Burnouf T, Goubran HA, Chou ML, Devos D, Radosevic M Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Rev 2014, 28:155-166.
68. Simak J, Gelderman MP Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006, 20:1-26.
69. Goubran HA, Burnouf T, Stakiw J, Seghatchian J Platelet microparticle: a sensitive physiological "fine tuning" balancing factor in health and disease. Transfus Apher Sci 2015, 52:12-18.
70. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002, 30:450-459.
71. Andaloussi SE, Mäger I, Breakefield XO, Wood MJ Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013, 12:347-357.
72. van Dommelen SM, Vader P, Lakhal S, Kooijmans SA, van Solinge WW, Wood MJ, et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 2012, 161:635-644.
73. Delabranche X, Berger A, Boisramé-Helms J, Meziani F Microparticles and infectious diseases. Med Mal Infect 2012, 42:335-343.
74. Harrison P, Cramer EM Platelet alpha-granules. Blood Rev 1993, 7:52-62.
75. van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012, 64:676-705.
76. Laffont B, Corduan A, Ple H, Duchez A-C, Cloutier N, Boilard E, et al. Activated platelets can deliver mRNA regulatory Ago2.microRNA complexes to endothelial cells via microparticles. Blood 2013, 122:253-261.
77. Clancy JW, Sedgwick A, Rosse C, Muralidharan-Chari V, Raposo G, Method M, et al. Regulated delivery of molecular cargo to invasive tumour-derived microvesicles. Nat Commun 2015, 6:6919.
78. Goubran H, Sabry W, Kotb R, Seghatchian J, Burnouf T Platelet microparticles and cancer: an intimate cross-talk. Transfus Apher Sci 2015, 53:168-172.
79. Cognasse F, Hamzeh-Cognasse H, Laradi S, Chou ML, Seghatchian J, Burnouf T, et al. The role of microparticles in inflammation and transfusion: a concise review. Transfus Apher Sci 2015, 53:159-167.
80. Burnouf T, Chou ML, Goubran H, Cognasse F, Garraud O, Seghatchian J An overview of the role of microparticles/microvesicles in blood components: are they clinically beneficial or harmful?. Transfus Apher Sci 2015, 53:137-145.
81. Bruno S, Camussi G Role of mesenchymal stem cell-derived microvesicles in tissue repair. Pediatr Nephrol 2013, 28:2249-2254.
82. Biancone L, Bruno S, Deregibus MC, Tetta C, Camussi G Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 2012, 27:3037-3042.
83. Lener T, Gioma M, Aigner L, Börger V, Buzas E, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles 2015, 4:30087.
84. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release 2015, 207:18-30.
85. Mause SF, Weber C Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010, 107:1047-1057.
86. Rank A, Nieuwland R, Crispin A, Grutzner S, Iberer M, Toth B, et al. Clearance of platelet microparticles in vivo. Platelets 2011, 22:111-116.